Navigation Links
Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration
Date:2/10/2010

PLANTATION, Fla. and DALLAS, Feb. 10 /PRNewswire/ -- Goodwin Biotechnology Inc., a full service Contract Biomanufacturing Company and Macrocyclics, Inc., a manufacturer of customized chelating agents, jointly announced today their collaborative agreement on Chelation and Bioconjugation.  The collaboration will strengthen joint customer projects in Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing.

"Clinical development programs in nuclear medicine with biotargeted agents require combining chelation chemistry and bioconjugation chemistry to create a product," said Garry E. Kiefer, Ph.D., Chief Executive Officer at Macrocyclics.   "In Goodwin Bio, we found a perfect collaborator to jointly advance diagnostic and therapeutic medicine."

"We are excited about collaborating with Macrocyclics, a company dedicated to the leading-edge development of new chelation chemistry platforms," said Muctarr Sesay, Ph.D., Vice President of Process Development at Goodwin Bio.  "Our integrated cGMP services combined with Macrocyclics' chelation expertise will enhance clinical development programs in nuclear medicine."

About Goodwin Biotechnology, Inc.

Goodwin Bio, (GBI) located in Plantation, FL., is a full service contract biomanufacturing company and specializes in process development and cGMP production of protein based therapeutics for pre-clinical and early phase clinical trials. The products manufactured by Goodwin Bio are being used in clinical trials and the Company has assisted in the preparation of several IND filings for various clients.  GBI caters small to midsize biotech companies, universities, cancer research institutes and various branches of the U.S. Government.

About Macrocyclics, Inc:

Macrocyclics, (Macrocyclics, Inc.) located in Dallas, TX., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine. A broad library of catalog products designed to meet the needs of basic and applied research customers as well as custom cGMP products and services to accelerate clinical development programs are provided.  Clients are international and include government agencies, scientific investigators, biotech and pharmaceutical companies.

SOURCE Goodwin Biotechnology Inc.


'/>"/>
SOURCE Goodwin Biotechnology Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
3. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
6. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
7. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
8. Leading Biotechnology Company Grows with StayinFront CRM
9. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and Company) ... today that it will host a live webcast of its Annual ... (ET). The webcast can be accessed from the ... replay through Tuesday, January 31, 2017. ... About BD BD is a global ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
Breaking Biology Technology:
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
Breaking Biology News(10 mins):